% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • Dooper55 Dooper55 Nov 17, 2009 8:13 AM Flag

    Deutsche Bank Initiates Coverage on Omeros Corp (OMER) with a Buy; Emerging Pharmaceutical Company

    November 17, 2009 7:31 AM EST

    Deutsche Bank initiates coverage on Omeros Corp (Nasdaq: OMER) with a Buy rating and a $15 price target.

    Deutsche analyst says, "Omeros is an emerging pharmaceutical company with a late-stage clinical program based on an innovative approach for improving post-surgical outcomes. We believe that the three PharmacoSurgery candidates—OMS103HP for arthroscopy, OMS302 for ophthalmic surgery, and OMS201 for urology—can potentially garner aggregate peak worldwide sales of $1 billion+. Omeros also has a deep preclinical pipeline of programs targeting large underserved markets...In our opinion, at an inexpensive $160 million valuation (technology valuation of $110 million), Omeros’ stock is very attractively priced, given its late stage PharmacoSurgery product portfolio. In fact, based on expected profits from sales of OMS103HP alone, we derive our 12-month price target of $15 (NPV is $11-12), based on 22x our fully taxed 2013 EPS estimate of $1.15, which we discount at 30%."

    To see more analyst ratings on OMER Click Here.

    Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
10.52-0.03(-0.28%)Jun 30 4:00 PMEDT